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The membrane glycoprotein encoded by the env gene of either the polycythemia- or anemia-inducing spleen focus-forming
virus (SFFVp or SFFVa, respectively) is responsible for the induction of erythroleukemia in mice. It has been shown that the
SFFVp glycoprotein, gp55, interacts with the erythropoietin receptor (EPO-R) and promotes EPO-independent proliferation of
an EPO-R-expressing hematopoietic cell line, Ba/F3 (Li et al., Nature 343:762, 1990). We show here that when residues within
the transmembrane (TM) sequence of an SFFVp gp55 are altered based on the sequences of the anemia-inducing gp55s by
a methionine-to-isoleucine (M-I) substitution, a di-leucine deletion (dLL), or both, the resulting mutants display an attenuated
phenotype that resembles an SFFVa: they induce milder erythroproliferative disease without polycythemia in vivo and are
unable to promote EPO-independent cell proliferation in vitro. The dLL mutation directly interferes with EPO-R binding by
decreasing the affinity of gp55 for the receptor. On the other hand, the M-I mutation hampers the full mitogenic activation
of EPO-R while having no effect on receptor binding and asserts a dominant negative effect over the wild-type SFFVp gp55.
Two other sequence changes within the TM sequence did not affect the biological activities of the SFFVp gp55. These results
indicate that the TM sequence of the SFFV env glycoprotein plays a prominent role in SFFV-induced erythroleukemogenesis
through its influence on the mitogenic activation of EPO-R. © 1998 Academic Press
INTRODUCTION
Several different strains of Friend spleen focus-form-
ing virus (F-SFFV) and one Rauscher SFFV (R-SFFV) have
been isolated (Axelrod and Steeves, 1964; Friend, 1957;
Lilly and Steeves, 1973; Mirand et al., 1968; Rauscher,
1962). All cause an acute erythroleukemia that is mani-
fested by a prolonged proliferation of erythroprecursor
cells in susceptible adult mice. However, disease in-
duced by the anemia-inducing SFFV (SFFVa) strains (in-
cluding the original F-SFFVa and R-SFFV) is accompa-
nied by a normal to slightly anemic condition, whereas
that induced by the polycythemia-inducing SFFV (SFFVp)
strains, which are all derived from the F-SFFVa, develops
more rapidly with an overproduction of erythrocytes, re-
sulting in a polycythemic condition (Axelrod and Steeves,
1964; Lilly and Steeves, 1973; Mirand et al., 1968). In
addition, erythroid precursors infected by the two types
of viruses also differ in their requirements for erythropoi-
etin (EPO) during proliferation and differentiation in vitro,
whereas the SFFVp-infected colony-forming unit-eryth-
roid (CFU-E) or burst-forming unit-erythroid (BFU-E) cells
are capable of forming hemoglobinized colonies in the
absence of EPO, the formation of similar erythroid colo-
nies from SFFVa-infected cells requires the addition of
EPO (Hankins et al., 1978; Hankins and Troxler, 1980).
Previous experiments have shown that the membrane
glycoprotein, gp55, encoded by the env gene is highly
conserved among different SFFV strains and is responsible
for causing the erythroleukemia (Amanuma et al., 1983;
Bestwick et al., 1984; Clark and Mak, 1983; Linemeyer et al.,
1981, 1982). The molecular mechanism for SFFV-induced
leukemogenesis was first suggested by the findings that
gp55 from one of the SFFVp strains was able to interact
with the receptor for EPO (EPO-R) (Li et al., 1990) and that
this interaction was capable of converting either an IL-3-
dependent hematopoietic cell line, Ba/F3 (Li et al., 1990), or
an EPO-dependent erythroleukemia line (Ruscetti et al.,
1990) to growth factor independence. Further studies have
shown that the mitogenic signal is activated only when both
gp55 (Ferro et al., 1993; Wang et al., 1993) and EPO-R (Li et
al., 1995) are expressed at the cell surface. In addition,
studies have established that cell surface expression of
gp55 is critical for its leukemogenicity in vivo (Li et al., 1987;
Wang et al., 1993). These results indicate that gp55 acti-
vates a mitogenic signaling pathway through its interaction
with EPO-R at the cell surface, resulting in uncontrolled
erythroid proliferation that ultimately leads to leukemia.
However, it is not clear whether gp55 encoded by the
SFFVa strains interacts with EPO-R and induces erythroleu-
kemia through a similar mechanism.
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It has been shown that the transmembrane (TM) se-
quence of gp55 may determine the anemia- or polycy-
themia-inducing phenotype of SFFVs (Chung et al., 1987,
1989) and that mutations within the TM sequence of an
SFFVp gp55 may directly affect its leukemogenicity (Wa-
tanabe et al., 1995). To further study the potential role that
gp55 TM sequence may play in the SFFV-induced leuke-
mogenesis, we introduced several mutations into the TM
sequence of an SFFVp gp55 based on the SFFVa se-
quences. Our results show that the function of the SFFVp
gp55 can be severely affected by mutations in the TM
sequence.
RESULTS
Construction of the gp55 TM mutants
A comparison of the TM sequences from different
SFFV strains, as noted previously (Bestwick et al., 1984;
Wolff et al., 1985), shows that two characteristics consis-
tently present in the SFFVp but not in the SFFVa se-
quences may be responsible for the conversion of the
anemia- to the polycythemia-inducing phenotype (Fig.
1A): an I-to-M substitution at position 390 and a di-
leucine (dLL) duplication at positions 396 and 397. In
addition, a phenylalanine residue (F) at position 404 of
the SFFVa sequences is changed to either an I or L in the
SFFVp sequences. To study the possible effects of these
sequence differences on the pathogenicity of the SFFV,
we changed the coding sequence of an SFFVp gp55
[shown as F-SFFVp(1) in Fig. 1A] and made several
mutant constructs (Fig. 1B): TM-SFa, with the entire TM
sequence derived from anemia-inducing R-SFFV gp55;
TM-MI, with an M-to-I substitution at position 390; TM-
dLL, with a deletion of the dLL residues at positions 396
and 397; TM-MIdLL, with both the MI and dLL mutations;
and TM-IF, with an I-to-F change at position 404. In
addition, mutant TM-YH, with a Y-to-H change at position
408, was made. Because the other two SFFVp gp55
sequences contained an H residue at position 408 (Fig.
1A), the Y-to-H mutation was not expected to affect the
activity of the SFFVp gp55.
Normally, a small fraction of the intracellular gp55 is
further processed into a slightly larger form, gp55p, in the
Golgi apparatus and transported to the cell surface
(Dresler et al., 1979; Wang et al., 1993) where it binds to
EPO-R (Casadevall et al., 1991; Ferro et al., 1993) and
exerts its biological activity (Li et al., 1987, 1995; Wang et
al., 1993). To make certain that mutations in the TM
sequence did not affect the processing of gp55 and its
transport to cell surface, we next examined the process-
ing of the TM mutants. Because the expression of the
amphotropic MuLV gp70 in either the fibroblast packag-
ing (Bestwick et al., 1988) or the Ba/F3 (Ferro et al., 1993)
cells may interfere our analysis, we examined gp55 pro-
cessing in the human 293T cells transiently expressing
the TM mutants. As shown in Fig. 2, gp55p was found
from cells expressing TM-YH (lane 3), TM-MI (lane 4),
TM-dLL (lane 5), and TM-MIdLL (lane 6), indicating that
mutations in the TM sequence did not significantly affect
gp55 processing and transport to the cell surface. Al-
though the amount of the processed form for these
mutants varied slightly in comparison with that of SFFVp
(lane 8), no consistent difference in gp55p was observed
for any of these mutants (data not shown). The pro-
cessed TM-SFa was reproducibly less (lane 7) than that
of the SFFVp gp55 (lane 8) but was comparable with the
FIG. 2. Analysis of the TM mutant gp55p expression. Proteins ex-
tracted from ;105 293T cells transfected with a control plasmid (lane
2), or plasmids containing the proviral sequences of TM-YH (lane 3),
TM-MI (lane 4), TM-dLL (lane 5), TM-MIdLL (lane 6), TM-SFa (lane 7),
SFFVp (lane 8), or R-SFFV (lane 9) were analyzed in Western blotting
using anti-gp55 monoclonal and horse radish peroxidase-conjugated
rabbit anti-rat antibodies (Sigma) in a standard ECL method. Cells
expressing an internal truncated gp55 encoded by a mitogenic SFFVp
variant (Fang et al., unpublished data), PL-R2 (lane 1) were also in-
cluded as a control.
FIG. 1. A comparison of the gp55 TM sequences. Sequences of
various TM mutants (B) and revertants (C) are aligned with that of the
wild-type SFFVs (A) including F-SFFVp(1) (Wolff et al., 1983), F-SFFVp(2)
(Clark and Mak, 1983), F-SFFVp(3) (Amanuma et al., 1983), F-SFFVa
(Wolff et al., 1985), and R-SFFV (Bestwick et al., 1984). Amino acid
residues at positions 390, 396, and 397 are shown in bold. Identical
residues (:) and corresponding residues that are absent (-) are shown.
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processed SFFVa (R-SFFV) gp55 (lane 9). This result is
consistent with the previous observation that the SFFVa
gp55 is less efficiently processed (Ruscetti et al., 1981)
and suggests that TM sequence characteristics other
than I390 or the lack of L396L397 may influence SFFVa
gp55 processing.
Pathogenesis of the TM mutant SFFVs
We next examined the leukemogenicity of the TM
mutants. NIH Swiss mice infected with the mutant vi-
ruses were killed 2 or 3 weeks after infection, and their
spleen weight and hematocrit were measured. As shown
in Table 1, TM-SFa, TM-MI, TM-dLL, and TM-MIdLL mu-
tants, like the anemia-inducing R-SFFV, had properties
similar to that of an SFFVa: they induced a relatively
milder splenomegaly and the infected mice had an ap-
parently normal hematocrit. In contrast, mutants TM-YH
and TM-IF had properties similar to that of the SFFVp and
induced a more severe splenomegaly as well as polycy-
themia. These results indicate that both the I-to-M sub-
stitution at position 390 and the dLL duplication at posi-
tions 396 and 397, but not the F-to-I sequence change at
position 404, contribute to the increased leukemogenic-
ity and the ability to induce polycythemia. The Y-to-H
mutation at position 408, as expected, had no effect on
the biological activities of the SFFVp gp55.
Mitogenesis of the gp55 TM mutants in the Ba/F-ER
cells
To examine whether the gp55 TM mutants could pro-
mote EPO-independent proliferation, the EPO-R express-
ing Ba/F3 (called Ba/F-ER) cells infected with each of the
neo-containing mutant viruses (see Materials and Meth-
ods) were first selected by growing the cultures in me-
dium containing G-418 and EPO to avoid possible varia-
tions in virus titers. Analysis of the individual clones
isolated from the G-418-resistant cell populations after
infections showed that 100% of the clones were infected
with the viruses and expressed gp55 (data not shown).
The abilities of the gp55 TM mutants to promote EPO-
independent cell proliferation were then analyzed by
growing the infected Ba/F-ER cells at different densities
in medium with or without added EPO. As shown in Table
2, TM mutants with an apparent SFFVa(R-SFFV) pheno-
type including TM-SFa, TM-MI, TM-dLL, and TM-MIdLL
formed EPO-independent Ba/F-ER clones at frequencies
at least 10- to 100-fold lower than those infected with the
SFFVp-like YH and IF viruses indicating that the mito-
genic activation of EPO-R by gp55 was also affected by
the M-I and/or dLL mutations. Furthermore, the appear-
ance of the rare EPO-independent clones from the
SFFVa-like virus-infected Ba/F-ER cells (Table 2) was due
to the emergence of revertants rather than a low mito-
genic activity of the gp55 mutants, as DNA sequence
analysis of the env genes cloned from several of the
EPO-independent lines derived from the TM-MI, TM-dLL
,or TM-MIdLL virus-infected Ba/F-ER cells showed that
all had reverted to the SFFVp wild-type at positions 390,
396, and 397 in the TM sequence (Fig. 1C). Taken to-
gether, these results indicate that the SFFVa-like gp55s
are incapable of inducing EPO-independent proliferation
of the Ba/F-ER cells and suggest that both the I-to-M
TABLE 1
Pathogenesis of SFFV TM Mutants
Virus Time Spleen weight (g/hematocrit) Average
Uninfected Week 2 N.D.
Week 3 0.16 (42%), 0.15 (46%), 0.13 (48%), 0.14 (48%), 0.19 (48%) 0.15 (46%)
R-MuLV Week 2 0.10 (45%), 0.12 (46%), 0.14 (50%), 0.14 (50%), 0.12 (52%) 0.12 (48%)
Week 3 0.21 (41%), 0.17 (42%), 0.26 (40%), 0.18 (43%), 0.19 (46%), 0.18 (48%) 0.20 (43%)
SFFVp Week 2 1.13 (55%), 0.59 (64%), 1.26 (67%), 0.21 (54%), 0.21 (51%), 0.63 (66%) 0.67 (60%)
Week 3 4.03 (90%), 2.98 (85%), 1.21 (60%), 3.66 (72%), 2.52 (80%) 2.88 (77%)
R-SFFV Week 2 0.14 (51%), 0.13 (56%), 0.23 (55%), 0.11 (54%), 0.36 (59%) 0.19 (55%)
Week 3 0.70 (48%), 0.74 (54%), 0.52 (48%), 0.37 (58%) (two died) 0.58 (52%)
TM-SFa Week 2 0.50 (55%), 0.54 (55%), 0.58 (58%), 0.47 (56%), 0.23 (54%), 0.19 (53%) 0.42 (55%)
Week 3 0.30 (46%), 0.39 (51%), 0.60 (41%), 1.10 (50%), 0.22 (47%), 0.32 (46%), 0.17 (41%), 0.71 (41%) 0.48 (45%)
TM-MI Week 2 0.88 (49%), 0.51 (53%), 0.50 (51%), 0.43 (58%), 0.59 (45%), 0.60 (47%) 0.59 (51%)
Week 3 0.71 (50%), 0.52 (49%), 0.47 (57%), 0.40 (46%), 0.72 (53%), 1.26 (49%), 0.26 (51%) 0.62 (51%)
TM-dLL Week 2 0.17 (53%), 0.14 (56%), 0.16 (54%), 0.20 (50%) 0.17 (53%)
Week 3 0.28 (47%), 0.81 (50%), 0.27 (47%), 0.38 (49%), 0.37 (45%), 0.18 (44%) 0.38 (47%)
TM-MIdLL Week 2 0.39 (52%), 0.22 (51%), 0.19 (54%), 0.48 (54%), 0.19 (60%), 0.26 (60%) 0.29 (55%)
Week 3 0.30 (50%), 0.66 (48%), 0.27 (48%), 0.60 (41%), 0.32 (45%), 0.31 (45%), 0.39 (49%) 0.41 (47%)
TM-YH Week 2 1.98 (68%), 1.37 (45%), 1.80 (67%), 1.52 (69%), 2.35 (63%), 0.5 (62%) 1.59 (62%)
Week 3 2.03 (80%), 1.60 (55%), 2.59 (82%), 1.76 (85%), 1.74 (78%) 1.94 (76%)
TM-IF Week 2 1.62 (55%), 1.85 (52%), 0.68 (60%), 1.53 (65%), 1.01 (55%) 1.34 (59%)
Week 3 4.09 (82%), 0.61 (78%), 1.34 (62%), 3.04 (80%), 2.11 (54%), 1.66 (70%) 2.14 (71%)
Note. N.D. 5 not determined.
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substitution at position 390 and the dLL duplication at
positions 396 and 397 in TM sequence contributed to the
increased mitogenicity of the SFFVp gp55.
Formation of erythroid colonies from the SFFV TM
mutant infected progenitors
One prominent feature of the SFFVp-infected erythroid
progenitors is that they are capable of forming EPO-
independent CFU-E colonies in vitro. In contrast, the
SFFVa-infected erythroid progenitors still depends on the
presence of EPO for the maximal formation of such
colonies (Horoszewicz et al., 1975; Liao and Axelrad,
1975; Steinheider et al., 1979). To analyze the EPO re-
quirement of the SFFV TM mutant-infected erythroid pro-
genitors, spleen cell suspensions made from mice in-
fected with various SFFV viruses were placed in methyl-
cellulose medium for 48 h in the presence or absence of
EPO and CFU-E colony formation was determined. As
shown in Table 3, while erythroid progenitors infected
with the SFFVp or TM-YH mutant viruses were capable of
forming large numbers of EPO-independent CFU-E col-
onies, those infected with the SFFVa-like viruses, includ-
ing TM-MI, TM-dLL, TM-MIdLL, and TM-SFa, formed
colonies that remained EPO dependent. These data sug-
gest that the low mitogenicity of gp55 is also responsible
for the inability of the SFFVa-like viruses to promote
EPO-independent growth of the erythroid progenitors in
vitro.
Interaction between the gp55 TM mutants and EPO-R
It has been shown that the SFFVp gp55 binds to EPO-R
and that such interaction may be critical for the SFFV-
induced erythroid proliferation (Casadevall et al., 1991;
Ferro et al., 1993; Li et al., 1990). We therefore examined
EPO-R binding by the various gp55 TM mutants in sev-
eral Ba/F-ER cell lines coexpressing EPO-R (Fig. 3A) and
gp55 (Fig. 3B), using a combined anti-gp55 immunopre-
cipitation (IP)/anti-EPO-R Western blot analysis (Li et al.,
1995). As shown in Fig. 3C, all of the gp55 mutants
without the L396L397 duplication in the TM sequence
including TM-dLL (lane 5), TM-MIdLL (lane 6), and TM-
SFa (lane 7), like the R-SFFV gp55 (lane 8), had a lower
affinity for EPO-R than the wild-type SFFVp gp55 (lane 2)
or the TM-YH mutant (lane 3). In addition, mitogenic
revertants derived from the SFFVa-like mutants isolated
from the growth factor-independent Ba/F-ER lines (Table
2) that regained the dLL duplication interacted strongly
with EPO-R (data not shown). These data suggest that
the dLL duplication found in all three of the SFFVp se-
TABLE 2
EPO-Independent Growth of Ba/F-ER Cells Infected
with the TM Mutants
Fraction of wells with cell growth in medium
Without EPOa With EPO (0.2 u/ml)
Inoculation density (cells/well)
Virus 104 103 102 103 102 101
Mock 0/16 0/16 0/16 16/16 15/16 1/16
SFFVp 16/16 16/16 4/16 16/16 16/16 4/16
R-SFFV 2/16 0/16 0/16 16/16 11/16 0/16
TM-SFa 10/16 2/16 0/16 16/16 15/16 5/16
TM-YH 16/16 16/16 5/16 16/16 16/16 1/16
TM-IF 16/16 14/16 3/16 N.D. N.D. N.D.
TM-MI 15/16 2/16 0/16 16/16 16/16 2/16
TM-dLL 5/16 1/16 0/16 16/16 14/16 1/16
TM-MIdLL 1/16 0/16 0/16 16/16 11/16 4/16
Note. N.D., not determined.
a Sixteen wells of 96-well plates were seeded with cells at the
indicated densities, and positive cell growth was scored 2 weeks later.
TABLE 3
CFU-E in Spleen of Mice Infected with the SFFV TM Mutants
Virus
CFU-E per 105 spleen cells (mean 6 SD)a
2EPO 1EPOb
R-MuLV 7 6 4 61 6 24
SFFVp 2514 6 31 2387 6 267
R-SFFV 7 6 12 57 6 6
TM-YH 1807 6 210 2040 6 227
TM-MI 163 6 106 1925 6 135
TM-dLL 45 6 27 960 6 20
TM-MIdLL 30 6 10 1026 6 311
TM-SFa 57 6 42 607 6 152
a Values were calculated based on the results of triplicate cultures.
b EPO was added at 0.5 u/ml.
FIG. 3. Analysis of the gp55-EPO-R interaction. Proteins extracted
from equal numbers of uninfected (lane 1) or SFFVp (lane 2), TM-YH
(lane 3), TM-MI (lane 4), TM-dLL (lane 5), TM-MIdLL (lane 6), TM-SFa
(lane 7), or R-SFFV (lane 8) virus-infected Ba/F-ER cells were either
analyzed by anti-EPO-R (A) or anti-gp55 (B) Western blotting or they
were first precipitated with anti-gp55 monoclonal antibodies, and the
coprecipitated EPO-R was then analyzed by anti-EPO-R Western blot-
ting (C).
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quences (Fig. 1A) may increase the affinity of gp55 for
EPO-R, resulting in a more potent viral protein that is
capable of inducing EPO-independent erythroprolifera-
tion in vitro and a more rapid erythroproliferative disease
in vivo.
Interestingly, the M390-to-I390 substitution did not affect
the apparent affinity of gp55 for EPO-R (Fig. 3, lane 4).
One possibility is that the MI mutation may instead in-
terfere with the full mitogenic activation of EPO-R by
gp55 at a postbinding step. If so, one prediction would be
that such a mutation may have a dominant negative
effect over the wild-type SFFVp gp55. To examine this
possibility, we superinfected several of the TM mutant-
infected Ba/F-ER clones with the wild-type SFFVp and
analyzed the growth of these cells. As shown in Table 4,
while Ba/F-ER clones infected with any of the other
SFFVa-like TM mutants were converted by SFFVp to EPO
independence at similar frequencies as the uninfected
Ba/F-ER clones, no EPO-independent growth was ob-
served for the two TM-MI expressing clones after SFFVp
superinfection. This was not due to a decreased in-
fectibility of the TM-MI virus-infected clones as superin-
fection with another retrovirus carrying the cDNA for IL-3
efficiently converted these cells to growth-factor inde-
pendence (Table 4). Thus these results suggest that the
TM-MI mutant, through its interaction with EPO-R, exerts
a dominant negative effect over the wild-type SFFVp
gp55.
DISCUSSION
The two types of SFFVs exhibit both common and
distinct characteristics. In vivo, both induce a prolonged
proliferation of erythroid precursor cells that eventually
leads to erythroleukemia (Axelrod and Steeves, 1964;
Friend, 1957; Lilly and Steeves, 1973; Mirand et al., 1968;
Rauscher, 1962). However, the proliferative disease in-
duced by SFFVp develops rapidly and is accompanied by
polycythemia, while that induced by the SFFVa (R-SFFV)
develops slower with the infected animals having a he-
matocrit ranging from normal to slightly anemic (Table 1).
In addition, erythroid precursors infected with SFFVa
form 5- to 10-fold fewer EPO-independent B-FUE or
CFU-E colonies than those infected with SFFVp (Hankins
and Troxler, 1980; Horoszewicz et al., 1975; Liao and
Axelrad, 1975; Steinheider et al., 1979, and see Table 3).
This difference in EPO dependence of the infected ery-
throid cells was reflected in our TM mutant studies: only
mutants with the phenotype of a fully pathogenic SFFVp
were able to induce EPO-independent growth of either
the Ba/F-ER (Table 2) or the CFU-E cells (Table 3) in vitro.
These results are consistent with the hypothesis that the
mitogenic activity of gp55 is a major determinant for the
SFFV-induced erythroleukemia. Furthermore, they sug-
gest that the high mitogenicity of the SFFVp gp55 may
also be responsible for the induction of polycythemia,
possibly through promoting the proliferation of the more
mature erythroblasts in vivo.
Previous studies suggest that the mitogenic interac-
tion between the SFFVp gp55 and EPO-R is responsible
for the virus-induced erythroid proliferation (Casadevall
et al., 1991; Ferro et al., 1993; Li et al., 1995; 1990). Our
results from the gp55 TM mutant studies strongly sup-
port this hypothesis. First, all gp55 mutants without the
L396L397 duplication, including TM-dLL, TM-MIdLL, and
TM-SFa, had a reduced affinity for EPO-R (Fig. 3). This
low affinity correlated with their inability to promote EPO-
independent Ba/F-ER cell proliferation in vitro (Tables 2)
and an attenuation in their leukemogenicity in vivo (Table
1). Second, mitogenic revertants derived from some of
the TM mutants isolated from the EPO-independent Ba/
F-ER lines strongly interacted with EPO-R (data not
shown), and sequence analysis of several such rever-
tants showed that they all contained the L396L397 dupli-
cation (Fig. 1C). Third, the TM-MI mutant, through its
strong binding to EPO-R (Fig. 3C, lane 4), exerted a
dominant negative effect and abrogated the mitogenic
activation of EPO-R by the wild-type SFFVp gp55 (Table
4). Taken together, these results suggest that a full mi-
togenic activation of EPO-R by gp55 is required for the
SFFVp-induced EPO-independent erythroproliferation.
Cell surface expression of the SFFVp gp55 has been
demonstrated to be critical for its mitogenic activity in
vitro (Ferro et al., 1993; Li et al., 1990, 1995; Wang et al.,
1993) and leukemogenicity in vivo (Li et al., 1987; Wang et
al., 1993). Our finding that the TM-MI, TM-dLL, and TM-
MIdLL gp55s were efficiently processed (Fig. 2) suggests
that the attenuated phenotype of these mutants results
from a reduced ability to bind and/or activate EPO-R, not
TABLE 4
Dominant Negative Effect of the TM-MI Mutant
Ba/F-ER line
Factor-independent growtha
after superinfection with
SFFVp SF/IL-3
103 102 103 102
Uninfected
Line 1 9/24 2/24 16/24 13/24
Line 2 15/24 4/24 24/24 24/24
TM-SFa/BE
Line 1 8/24 3/24 24/24 24/24
TM-MI/BE
Line 1 0/24 0/24 17/24 7/24
Line 2 0/24 0/24 13/24 5/24
TM-dLL/BE
Line 1 11/24 2/24 23/24 14/24
Line 2 7/24 0/24 15/24 3/24
a Twenty-four wells of a 96-well plate were seeded with the Ba/F-ER
lines at the indicated inoculation densities (cells/well), and cell growth
was scored 2 weeks later.
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from a lack of gp55 cell surface expression. The fact that
the TM-MI mutant exerts a dominant negative effect over
the wild-type SFFVp gp55 (Table 4) and that a normal
level of EPO-Rs as measured by radiolabeled EPO bind-
ing (data not shown) or by the ability to sustain growth in
EPO medium (Table 2, and data not shown) is found at
the surface of the TM-MI mutant-infected Ba/F-ER cells is
consistent with a proper processing and cell surface
interaction of this mutant with EPO-R.
Previous observations have shown that the same gp55
sequence elements that affect the induction of both EPO-
independent erythroid proliferation in vitro (Chung et al.,
1989) and erythroleukemia in vivo (Watanabe et al., 1995)
may overlap with those that determine the anemia- or
polycythemia-inducing phenotype of SFFVs (Chung et al.,
1987, 1989). Our results characterize the relative impor-
tance of the differences between the transmembrane
sequences of SFFVa (R-SFFV) and SFFVp gp55s. Specif-
ically, we have demonstrated that either the dLL or MI
mutation within the TM sequence generates an attenu-
ated phenotype resembles that of R-SFFV. Furthermore,
our findings that both the dLL and MI mutations interfere
with the mitogenic activation of EPO-R by the SFFVp
gp55 (Table 2) either at the binding (Fig. 3) or a postbind-
ing step (Fig. 3 and Table 4), respectively, and the fact
that the gp55s of the two SFFVs are otherwise highly
homologous (Wolff et al., 1985) suggest that both the
M390 and LL396/397 sequences may have been selected
during the evolution from the original F-SFFVa to the
mitogenically more active SFFVp viruses. This is further
supported by our findings that both of these mutations
quickly revert to the SFFVp sequence (Fig. 1C) either in
the Ba/F-ER cells (Table 2) or in mice (data not shown).
Given the ability ofan SFFVa to induce erythroprolifera-
tion in vivo, theweaker interaction between the SFFVa
gp55 and EPO-R (Fig. 3), although not sufficient to com-
pletely abrogate the requirement for EPO, may increase
the sensitivity to the hormone in vivo (Hankins and Trox-
ler, 1980), ultimately leading to erythroleukemia.
While it is clear that both the M390 and LL396/397 se-
quences of gp55 contribute to the abilities of an SFFVp to
promote EPO-independent erythroproliferation in vitro
and to induce polycythemia in vivo, it is not known
whether the induction of the mild anemia by the SFFVa
viruses is solely determined by the lack of these se-
quence characteristics. This is complicated by the fact
that other factors such as the monoclonal/oligoclonal
expansion of erythroleukemia cells that crowd out the
normal bone marrow erythroblasts during the late stage
of the disease (Kabat, 1989) and the blocking of terminal
differentiation in the infected erythroblasts by either
Spi-1 (Schuetze et al., 1993) or Stat5 (Fang et al., 1998)
may potentially lead to an anemic condition. Thus it is
possible that such an anemic condition is associated
with both the SFFVa- and SFFVp-induced diseases dur-
ing the late stage but is normally obscured by the con-
comitant induction of polycythemia in the SFFVp-infected
mice. Consistent with this hypothesis, it has been shown
that when virus replication is limited due to the absence
of a helper, which may reduce the number of the prolif-
erating erythroblasts undergoing terminal differentiation,
the disease induced by an SFFVp is accompanied by a
severe anemia (Spiro et al., 1988).
The fact that the dLL mutation interferes with EPO-R
binding by the SFFVp gp55 further suggests that the TM
sequences of the two proteins may be in direct contact
with each other. Alternatively, the TM mutation may affect
the overall structure and/or the proper membrane an-
chorage of gp55, therefore interferring with EPO-R bind-
ing indirectly. Our data cannot affirm these possibilities,
and we are conducting experiments to further study the
nature of the gp55–EPO-R interaction by using these and
other gp55 mutants.
MATERIALS AND METHODS
Cell growth and virus infection
Mouse NIH 3T3 fibroblasts or the human 293T cells
were maintained in DME medium plus 7.5% of calf serum
or 10% FCS, respectively. The Ba/F-ER cells (Li et al.,
1995) were grown in RPMI medium supplemented with
7.5% calf serum and 10% of WEHI-3 supernatant (as a
source of IL-3) or 0.2 U/ml EPO. For virus infection, ;5 3
105 Ba/F-ER cells were mixed with EPO (0.2 U/ml) and 2
ml of various supernatants collected from virus-produc-
ing c2 fibroblast packaging cells (Mann et al., 1983)
immediately before use. In addition, Polybrene (8 mg/ml,
Sigma) was added to facilitate infection. After 4 h of
incubation at 37°C, 2 ml of fresh medium containing 0.2
U/ml EPO was added, and the cultures were kept for 24 h
before they were transferred to G-418 (1 mg/ml)-contain-
ing medium, and the virus-infected (drug-resistant) cells
were obtained 1 week later. For growth analysis of the
virus-infected cells, they were harvested from cultures in
logarithmic growth, washed three times with RPMI me-
dium without supplements, resuspended at different
densities in aliquots of 0.1 ml RPMI medium containing
10% fetal bovine serum, and placed into 96-well microti-
ter plates as described previously (Li and Baltimore,
1991; Li et al., 1990). After 2 weeks of incubation, wells
with positive growth were scored, and cells were trans-
ferred to larger cultures for further analysis.
For analysis of the possible dominant negative effect
of the TM mutants, individual Ba/F-ER lines infected with
various mutants were first superinfected with SFFVp or
SF/IL-3 (see below). After incubation in IL-3-containing
medium for 24 h, they were switched to RPMI medium
without added growth factors and placed at different
densities in 96-well plates. After 2 weeks of incubation at
37°C, the numbers of wells with positive cell growth
were scored.
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TM mutant plasmids construction and revertant
cloning
To facilitate gp55 TM mutant construction, we first
engineered an XhoI and a ClaI site at NT1282 or NT1459
of the env sequence, respectively, in plasmid pSFneo (Li
et al., 1995) containing the proviral DNA of the Lilly-
Steeves SFFVp strain (Lilly and Steeves, 1973) and the
G-418 resistance marker. The XhoI insertion at NT1282
within the gp55-coding sequence did not affect the func-
tion of the SFFVp gp55 (Li et al., 1987). To obtain DNA
fragments containing the coding sequences for each of
the TM mutant constructs, a 59 oligonucleotide primer
(AGCATGGCTCGAGCCAAATT) based on the env se-
quence at NT1282 and the XhoI site and one of the 39
primers based on the coding sequences for the mutant
constructs (except SFa) and a ClaI site were then used to
amplify the plasmid containing the SFFVp sequence in
PCR. For mutant SFa construction or some of the TM
revertant cloning from the growth factor independent
Ba/F-ER lines, the same 59 primer and another 39 primer
based on sequence downstream of env and the ClaI site
were used to amplify plasmid pBC-10, which contained
the proviral DNA of R-SFFV (Bestwick et al., 1984) or
genomic DNA extracted from the Ba/F-ER lines, respec-
tively. All PCR DNA fragments were then ligated with
plasmid pBSK1 (Stratagene) for DNA sequence analysis.
After sequence verification, the mutant DNA fragments
were cloned into pSFneo (Li et al., 1995). Plasmids con-
taining the proviral sequences of the mutants were then
transfected into the c2 (Mann et al., 1983) or c2/PA317
1:1 mixed (Wang et al., 1993) fibroblast packaging cells or
293T using the standard calcium precipitation method.
The coding sequence for mouse IL-3 was obtained
using primers [GAATTCTC-AATCAGTGGCCGGGATAC-
CCA and CTCGAGACATTCCACGGTTCCACG-GTTAG,
based on the published sequence (Cambell et al., 1985)]
and cDNA templates prepared from the WEHI-3 cells in
PCR. The PCR clone was sequence verified and cloned
into an SFFV-based retroviral expression vector
(Bestwick et al., 1988). The resulting plasmid was trans-
fected into fibroblast packaging cells and virus (called
SF/IL-3) produced was used to infect the Ba/F-ER lines.
Analysis of leukemogenicity
Supernatants from the fibroblast packaging cell cul-
tures containing wild-type or TM-mutant SFFVs of similar
titers were mixed with Rauscher murine leukemia virus
(R-MuLV) helper, and 0.5 ml of the virus preparations was
injected into the tail veins of 4- to 6-week-old female NIH
Swiss mice. Control mice were either uninfected or in-
fected with R-MuLV alone. Splenomegaly and hematocrit
of the infected mice were examined after 14 or 21 days
by previously described methods (Li et al., 1986).
CFU-E colony assay
The CFU-E assay was based on protocols described
previously (Ahlers et al., 1994; Horoszewicz et al., 1975;
Liao and Axelrad, 1975; zharvSteinheider et al., 1979).
Briefly, splenocytes obtained from mice infected with
various SFFVs for 3 weeks were homogenized and dis-
sociated into a single cell suspension. The red blood
cells were then lysed by the NH4Cl buffer (0.83% NH4Cl,
0.1% NaHCO3, and 10 mM EDTA). Nucleated cell numbers
were then determined using a hemocytometer. Cell num-
bers were adjusted to 5 3 104 or 5 3 105 cells/ml in 0.5
ml of IMDM/10% FBS with or without EPO (0.5 U/ml) and
mixed with 1.5 ml of the EPO-minus CFU-E methylcellu-
lose medium (Stem Cell Technologies). Triplicates of cell
mixtures were placed in 12-well plates (0.5 ml/well) and
incubated for 2 days before the CFU-E colonies were
scored.
Immunoprecipitation and Western blot analyses
The gp55p expression was analyzed in Western blot-
ting using equal amounts of proteins extracted from the
human 293T cells 2 days after they were transfected with
various SFFV proviral plasmids and the anti-gp55 mono-
clonal antibody, 7C10 (Li et al., 1995). Western blot anal-
yses for the expression of EPO-R or gp55 in the Ba/F-ER
cells were carried out as described previously (Li et al.,
1995). Analysis of the interaction between gp55 and
EPO-R was carried out using a modified version of a
previously described immunoprecipitation–Western blot
method (Li et al., 1995). Briefly, ;106 of Ba/F-ER cells
expressing various gp55s at a similar level were lysed
with 0.5 ml of the culture supernatant containing the rat
anti-gp55 monoclonal, 7C10, 1% NP-40, and 0.04% NaN3,
and supernatants collected after a brief microcentrifuga-
tion were mixed with 50 ml of 5 M NaCl and 50 ml of
anti-rat IgG agarose (Sigma) and kept at 4°C overnight.
Proteins in the precipitates were then dissolved in SDS-
sample buffer and subjected to anti-EPO-R Western blot
analysis, using rabbit anti-EPO-R (Li et al., 1990) and
horseradish peroxidase-conjugated Protein A (Sigma) in
a standard ECL reaction.
ACKNOWLEDGMENTS
We thank D. Kabat for providing the plasmid for R-SFFV. We are
grateful to Qing-tian Niu and Guozhen Xu for technical assistance. This
research was supported by grant CA57335 from the National Cancer
Institute.
REFERENCES
Ahlers, N., Hunt, N., Just, U., Laker, C., Ostertag, W., and Nowock, J.
(1994). Selectable retrovirus vectors encoding Friend virus gp55 or
erythropoietin induce polycythemia with different phenotypic expres-
sion and disease progression. J. Virol. 68, 7235–7243.
Amanuma, H., Katori, A., Obata, M., Sagat, N., and Ikawa, Y. (1983).
Complete nucleotide sequence of the gene for the specific glyco-
52 FANG ET AL.
protein gp55 of Friend spleen focus-forming virus. Proc. Natl. Acad.
Sci. USA 80, 3913–3917.
Axelrod, A., and Steeves, R. (1964). Assay for Friend liekemia virus:
Rapid quantitative method based on enumeration of macroscopic
spleen foci in mice. Virology 24, 513–518.
Bestwick, R., Boswell, B., and Kabat, D. (1984). Molecular cloning of
biologically active Rauscher spleen focus-forming virus and se-
quences of its env gene and long terminal repeat. J. Virol. 51, 695–
705.
Bestwick, R., Kozak, S., and Kabat, D. (1988). Overcoming interference
to retroviral supinfection results in amplified expression of cloned
genes. Proc. Natl. Acad. Sci. USA 85, 5404–5408.
Cambell, H. D., Yner, S., Fung, M. C., and Young, I. G. (1985). Cloning
and nucleotide sequence of the murine interleukin-3 gene. Eur.
J. Biochem. 150, 297–304.
Casadevall, N., Lacombe, C., Muller, O., Gisselbrecht, S., and Mayeux,
P. (1991). Multimeric structure of the membrane erythropoietin recep-
tor of murine erythroleukemia cells (Friend cells). J. Bio. Chem. 266,
16015–16020.
Chung, S. W., Wolff, L., and Ruscetti, S. (1987). Sequences responsible
for the altered erythropoietin responsiveness in spleen focus-form-
ing virus strain SFFVP-infected cells are localized to a 678-base-pair
region at the 39 end of the envelope gene. J. Virol. 61, 1661–1664.
Chung, S. W., Wolff, L., and Ruscetti, S. K. (1989). Transmembrane
domain of the envelope gene of a polycythemia-inducing retrovirus
determines erythropoietin-independent growth. Proc. Natl. Acad. Sci.
USA 86, 7957–60.
Clark, S., and Mak, T. W. (1983). Complete nucleotide sequence of an
infectious clone of Friend spleen focus-forming provirus: gp55 is an
envelope fusion plycoprotein. Proc. Natl. Acad. Sci. USA 80, 5037–
5041.
Dresler, S., Ruta, M., Murray, M., and Kabat, D. (1979). Glycoprotein
encoded by the Friend spleen focus-forming virus. J. Virol. 30, 564–
575.
Fang, C., Choi, E., Nie, L. G., and Li, J.-P. (1998). Regulation of b-globin
expression through modulation of Stat5 activity. Submitted.
Ferro, F., Kozak, S., Hoatlin, M., and Kabat, D. (1993). Cell surface site for
mitogenic interaction of erythropoietin receptors with the membrane
glycoprotein encoded by Friend erythroleukemia virus. J. Biol. Chem.
268, 5741–5747.
Friend, C. (1957). Cell-free transmission in adult Swiss mice of a
disease having the character of a leukemia. J. Exp. Med. 105, 307–
318.
Hankins, D., Kost, T., Koury, M. J., and Krantz, S. (1978). Erythroid bursts
produced by Friend leukemia virus in vitro. Nature 276, 506–508.
Hankins, D., and Troxler, D. (1980). Polycythemia- and anemia-inducing
erythroleukemia ciruses exhibit differential erythroid transforming
effects in vitro. Cell 22, 693–699.
Horoszewicz, J. S., Leong, S. S., and Carter, W. A. (1975). Friend leuke-
mia: Rapid development of erythropoietin-independent hematopoi-
etic precursors. J. Natl. Cancer Inst. 54, 265–267.
Kabat, D. (1989). Molecular biology of Friend viral erythroleukemia.
Curr. Top. Microbiol. Immunol. 148, 1–42.
Li, J.-P., and Baltimore, D. (1991). Mechanism of leukemogenesis in-
duced by the MCF murine leukemia viruses. J. Virol. 65, 2408–2414.
Li, J.-P., Bestwick, R. K., Spiro, C., and Kabat, D. (1987). The membrane
glycoprotein of Friend spleen focus-forming virus: Evidence that the
cell surface component is required for pathogenesis and that it binds
to a receptor. J. Virol. 61, 2782–2792.
Li, J.-P., Hu, H. O., Niu, Q. T., and Fang, C. (1995). Cell surface activation
of the erythropoietin receptor by Friend spleen focus-forming virus
gp55. J. Virol. 69, 1714–1719.
Li, J.-P., Bestwick, R., Machida, C., and Kabat, D. (1986). Role of a
membrane glycoprotein in Friend viral erythroleukemia: Nucleotide
sequences of nonleukemogenic mutant and spontaneous revertant
viruses. J. Virol. 57, 534–538.
Li, J.-P., D’Andrea, A., Lodish, H., and Baltimore, D. (1990). Activation of
cell growth by binding of Friend spleen focus-forming virus gp55
glycoprotein ot the erythropoietin receptor. Nature 343, 762–764.
Liao, S. K., and Axelrad, A. A. (1975). Erythropoietin-independent ery-
throid colony formation in vitro by hemopoietic cells of mice infected
with friend virus. Int. J. Cancer 15, 467–482.
Lilly, F., and Steeves, R. A. (1973). B-tropic Friend virus: A host range
pseudotype of spleen focus-forming virus (SFFV). Virology 55, 363–
370.
Linemeyer, D., Rescetti, S., Scolnick, E., Evans, L., and Duesberg, P.
(1981). Biological activity of the spleen focus-forming virus is en-
coded by a molecularly cloned subgenomic fragment of the spleen
focus-forming virus DNA. Proc. Natl. Acad. Sci. USA 78, 1401–1405.
Linemeyer, D. L., Menke, G., Ruscetti, S. K., Evans, L. H., and Scolnick,
E. M. (1982). Envelope gene sequences which encode the gp52
protein of spleen focus-forming virus are required for the induction of
erythoid cell proliferation. J. Virol. 43, 223–233.
Mann, R., Mulligan, R. C., and Baltimore, D. (1983). Construction of a
retrovirus packaging mutant and its use to produce helper-free
defective retrovirus. Cell 33, 153–159.
Mirand, E., Steeves, R., Avila, L., and Grace, J. (1968). Spleen focus
formation by polycythemic strains of Friend leukemia virus. Proc.
Soc. Exp. Biol. Med. 127, 900–904.
Rauscher, F. J. (1962). A virus-induced disease of mice characterized by
erythrocytopoiesis and lymphoid leukemia. J. Natl. Cancer Inst. 29,
515–545.
Ruscetti, S., Janesch, N., A., C., Sawyer, S., and Hankins, D. (1990).
Friend spleen focus-forming virus induces factor independence in an
erythropoietin-dependent erythroleukemia cell line. J. Virol. 64, 1057–
1062.
Ruscetti, S. K., Feild, J. A., and Scolnick, E. M. (1981). Polycythaemia-
and anaemia-inducing strains of spleen focus-forming virus differ in
post-translational processing of envelope-related glycoproteins. Na-
ture 294, 663–665.
Schuetze, S., Stenberg, P. E., and Kabat, D. (1993). The Ets-related
transcription factor PU.1 immortalizes erythroblasts. Mol. Cell. Biol.
13, 5670–5678.
Steinheider, G., Seidel, H. J., and Kreja, L. (1979). Comparison of the
biological effects of anemia inducing and polycythemia inducing
Friend virus complex. Experientia 35, 1173–1175.
Spiro, C., Gliniak, B., and Kabat, D. (1988). A tagged helper-free Friend
virus causes clonal erythroblast immortality by specific proviral in-
tegration in the cellular genome. J. Virol. 62, 4129–4135.
Wang, Y., Kayman, S. C., Li, J. P., and Pinter, A. (1993). Erythropoietin
receptor (EpoR)-dependent mitogenicity of spleen focus-forming vi-
rus correlates with viral pathogenicity and processing of env protein
but not with formation of gp52-EpoR complexes in the endoplasmic
reticulum. J. Virol. 67, 1322–1327.
Watanabe, N., Yugawa, T., Ikawa, Y., and Amanuma, H. (1995). Both the
changes of six amino acids and the C-terminal truncation caused by
a one-base insertion in the defective env gene of Friend spleen
focus-forming virus significantly affect the pathogenic activity of the
encoded leukemogenic membrane glycoprotein (gp55). J. Virol. 69,
7606–7611.
Wolff, L., Kaminchik, J., Hankins, D., and Ruscetti, S. (1985). Sequence
comparisons of the anemia- and polycythemia-inducing strains of
Friend spleen focus-forming virus. J. Virol. 53, 570–578.
Wolff, L., Scolnick, E., and Ruscetti, S. (1983). Envelope gene of the
Friend spleen focus-forming virus: Deletion and insertions in 39
gp70/p15E-encoding region have resulted in unique features in the
primary structure of its protein product. Proc. Natl. Acad. Sci. USA 80,
4718–4722.
53SFFV gp55 TM SEQUENCE IN ERYTHROLEUKEMOGENESIS
